Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Renal cell carcinoma (CRCC) treated with anti-angiogenic molecules in the adjuvant setting: prognostic and therapeutic value alterations of the VHL gene and plasma and intratumoral expression of molecules involved in the pathway VHL / HIF / VEGF

Next Previous
X
Search
Trial Profile

Renal cell carcinoma (CRCC) treated with anti-angiogenic molecules in the adjuvant setting: prognostic and therapeutic value alterations of the VHL gene and plasma and intratumoral expression of molecules involved in the pathway VHL / HIF / VEGF

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 23 Aug 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sunitinib (Primary)
  • Indications Renal cell carcinoma
  • Focus Therapeutic Use
  • Acronyms S-TRAC

    • Most Recent Events

    • 04 Jul 2022 Results of meta analysis from KEYNOTE-564, S-TRAC, ASSURE, PROTECT, ATLAS, and SORCE, presented at the 37th Congress of the European Association of Urology
    • 20 Sep 2018 Status changed from recruiting to completed, according to results published in the Acta Oncologica.
    • 18 Oct 2016 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top